Cargando…
Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant
The newly emerged BA.2.75 SARS-CoV-2 variant exhibits an alarming 9 additional mutations in its spike (S) protein compared to the ancestral BA.2 variant. Here we examine the neutralizing antibody escape of BA.2.75 in mRNA-vaccinated and BA.1-infected individuals, as well as the molecular basis under...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413709/ https://www.ncbi.nlm.nih.gov/pubmed/36032970 http://dx.doi.org/10.1101/2022.08.14.503921 |
_version_ | 1784775816557625344 |
---|---|
author | Qu, Panke Evans, John P. Zheng, Yi-Min Carlin, Claire Saif, Linda J. Oltz, Eugene M. Xu, Kai Gumina, Richard J. Liu, Shan-Lu |
author_facet | Qu, Panke Evans, John P. Zheng, Yi-Min Carlin, Claire Saif, Linda J. Oltz, Eugene M. Xu, Kai Gumina, Richard J. Liu, Shan-Lu |
author_sort | Qu, Panke |
collection | PubMed |
description | The newly emerged BA.2.75 SARS-CoV-2 variant exhibits an alarming 9 additional mutations in its spike (S) protein compared to the ancestral BA.2 variant. Here we examine the neutralizing antibody escape of BA.2.75 in mRNA-vaccinated and BA.1-infected individuals, as well as the molecular basis underlying functional changes in the S protein. Notably, BA.2.75 exhibits enhanced neutralization resistance over BA.2, but less than the BA.4/5 variant. The G446S and N460K mutations of BA.2.75 are primarily responsible for its enhanced resistance to neutralizing antibodies. The R493Q mutation, a reversion to the prototype sequence, reduces BA.2.75 neutralization resistance. The mutational impact is consistent with their locations in common neutralizing antibody epitopes. Further, the BA.2.75 variant shows enhanced cell-cell fusion over BA.2, driven largely by the N460K mutation, which enhances S processing. Structural modeling revealed a new receptor contact introduced by N460K, supporting a mechanism of potentiated receptor utilization and syncytia formation. |
format | Online Article Text |
id | pubmed-9413709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-94137092022-08-27 Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant Qu, Panke Evans, John P. Zheng, Yi-Min Carlin, Claire Saif, Linda J. Oltz, Eugene M. Xu, Kai Gumina, Richard J. Liu, Shan-Lu bioRxiv Article The newly emerged BA.2.75 SARS-CoV-2 variant exhibits an alarming 9 additional mutations in its spike (S) protein compared to the ancestral BA.2 variant. Here we examine the neutralizing antibody escape of BA.2.75 in mRNA-vaccinated and BA.1-infected individuals, as well as the molecular basis underlying functional changes in the S protein. Notably, BA.2.75 exhibits enhanced neutralization resistance over BA.2, but less than the BA.4/5 variant. The G446S and N460K mutations of BA.2.75 are primarily responsible for its enhanced resistance to neutralizing antibodies. The R493Q mutation, a reversion to the prototype sequence, reduces BA.2.75 neutralization resistance. The mutational impact is consistent with their locations in common neutralizing antibody epitopes. Further, the BA.2.75 variant shows enhanced cell-cell fusion over BA.2, driven largely by the N460K mutation, which enhances S processing. Structural modeling revealed a new receptor contact introduced by N460K, supporting a mechanism of potentiated receptor utilization and syncytia formation. Cold Spring Harbor Laboratory 2022-08-15 /pmc/articles/PMC9413709/ /pubmed/36032970 http://dx.doi.org/10.1101/2022.08.14.503921 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Qu, Panke Evans, John P. Zheng, Yi-Min Carlin, Claire Saif, Linda J. Oltz, Eugene M. Xu, Kai Gumina, Richard J. Liu, Shan-Lu Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant |
title | Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant |
title_full | Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant |
title_fullStr | Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant |
title_full_unstemmed | Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant |
title_short | Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant |
title_sort | evasion of neutralizing antibody response by the sars-cov-2 ba.2.75 variant |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413709/ https://www.ncbi.nlm.nih.gov/pubmed/36032970 http://dx.doi.org/10.1101/2022.08.14.503921 |
work_keys_str_mv | AT qupanke evasionofneutralizingantibodyresponsebythesarscov2ba275variant AT evansjohnp evasionofneutralizingantibodyresponsebythesarscov2ba275variant AT zhengyimin evasionofneutralizingantibodyresponsebythesarscov2ba275variant AT carlinclaire evasionofneutralizingantibodyresponsebythesarscov2ba275variant AT saiflindaj evasionofneutralizingantibodyresponsebythesarscov2ba275variant AT oltzeugenem evasionofneutralizingantibodyresponsebythesarscov2ba275variant AT xukai evasionofneutralizingantibodyresponsebythesarscov2ba275variant AT guminarichardj evasionofneutralizingantibodyresponsebythesarscov2ba275variant AT liushanlu evasionofneutralizingantibodyresponsebythesarscov2ba275variant |